. . . . . . . "18"^^ . . . . "LIBImAb"@en . . "280"^^ . . . . . . . . . . . "Phase III Study in mCRC Patients With RAS/BRAF Wild Type Tissue and RAS Mutated in LIquid BIopsy to Compare in First-line Therapy FOLFIRI Plus CetuxiMAb or BevacizumaB (LIBImAb Study)"@en . "ensayo cl\u00EDnico"@es . . . "\u043A\u043B\u0456\u043D\u0456\u0447\u043D\u0435 \u0432\u0438\u043F\u0440\u043E\u0431\u0443\u0432\u0430\u043D\u043D\u044F"@uk . "clinical trial"@en . . . . . . "ensayu cl\u00EDnicu"@ast . . . . . . "NCT04776655" . . "2021-04-30T00:00:00Z"^^ . . "2023-04-29T00:00:00Z"^^ . . "Study in mCRC Patients RAS/BRAF wt Tissue and RAS Mutated LIquid BIopsy to Compare FOLFIRI Plus CetuxiMAb or BevacizumaB"@en . . . "Study in mCRC Patients RAS/BRAF wt Tissue and RAS Mutated LIquid BIopsy to Compare FOLFIRI Plus CetuxiMAb or BevacizumaB"@en . . . . . . . . . . . . . . . . . . . . . "klinisch onderzoek"@nl . . "Study in mCRC Patients RAS/BRAF wt Tissue and RAS Mutated LIquid BIopsy to Compare FOLFIRI Plus CetuxiMAb or BevacizumaB"@en . . . .